Beta
Mesalamine
medication Under reviewAn aminosalicylate medication used to treat inflammatory bowel disease, such as ulcerative colitis and Crohn's disease.
Research May Be Outdated
This habit has been flagged for a research update. Recent studies may not be included.
Research summary
Scientific studies, primarily randomized controlled trials and systematic reviews, demonstrate that mesalamine effectively induces and maintains remission in patients with mild-to-moderate ulcerative colitis, with topical formulations showing particular efficacy for proctitis and proctosigmoiditis. It exhibits a favorable safety profile comparable to placebo, with low rates of adverse effects across various dosing regimens including once-daily administration. No studies were identified evaluating mesalamine in healthy human subjects, as research focuses exclusively on individuals with inflammatory bowel disease.
No side effects tracked yet
No side effects have been reported by studies or users for this habit yet.
Related health conditions
Research showing how this habit affects specific health conditions. Always consult healthcare professionals.
May Help With
Chronic inflammatory bowel disease affecting the colon
The effect of hypochlorous acid on urine color among pediatric ulcerative colitis patients treated with mesalamine.
Löwenberg et al., Ma et al., Paridaens et al., Murray et al., Fiorino et al., Chen et al.
The Efficacy and Safety of Mesalamine and Probiotics in Mild‐to‐Moderate Ulcerative Colitis
Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: a systematic review and meta-analysis.
The continuing value of mesalazine as first-line therapy for patients with moderately active ulcerative colitis.
Oral mesalamine was effective and safe in maintaining remission in ulcerative colitis
Research (5 studies)
The continuing value of mesalazine as first-line therapy for patients with moderately active ulcerative colitis.
The effect of hypochlorous acid on urine color among pediatric ulcerative colitis patients treated with mesalamine.
Löwenberg et al., Ma et al., Paridaens et al., Murray et al., Fiorino et al., Chen et al.
The Efficacy and Safety of Mesalamine and Probiotics in Mild‐to‐Moderate Ulcerative Colitis
Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: a systematic review and meta-analysis.
Oral mesalamine was effective and safe in maintaining remission in ulcerative colitis
Community updates
No updates yet for this supplement.
Be the first to share your experience!